Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Mar 2016

Fathi Amir T, Lin William M, Durazzo Tyler, Piris Adriano, Sadrzadeh Hossein, Bernardo Lindsay, Borger Darrel R, McAfee Steven L, Kroshinsky Daniela, Chen Yi-Bin

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Squamous Cell
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Niacinamide

Share to Phenylurea Compounds

Share to Skin Neoplasms

Share to Sorafenib

Source

Identifiers

PMID: 25024084
DOI: 10.1200/JCO.2013.50.7582

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.PMID 25024084Read ↗

Dermatologic adverse events associated with targeted therapies for melanoma.Semantic proximity Read ↗

Dermatological adverse events from BRAF inhibitors: a growing problem.Semantic proximity Read ↗

Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation.Semantic proximity Read ↗

A retrospective analysis of drugs associated with the development of cutaneous squamous cell carcinoma reported by patients on the FDA’s adverse events reporting systemSemantic proximity Read ↗

Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.Semantic proximity Read ↗

[Sorafenib monotherapy for FLT3-ITD positive acute myeloid leukemia: a case report].Semantic proximity Read ↗

FGFR2 in the Development and Progression of Cutaneous Squamous Cell CancerSemantic proximity Read ↗

A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).Semantic proximity Read ↗

Nonmalignant cutaneous findings associated with vemurafenib.Semantic proximity Read ↗

[Ⅲ. Treatments for Skin Cancers Based on the Genetic Information].Semantic proximity Read ↗

A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation.Semantic proximity Read ↗

Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.